/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT
INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES/
SAN DIEGO, CA, Aug. 22 /CNW/ - Nventa Biopharmaceuticals Corporation
(TSX: NVN) announces the successful completion today of the closing of its
short form prospectus offering of units, resulting in the sale of 68,908,400
units at $0.125 per unit, for gross proceeds of $8,613,550. Each unit consists
of one common share of NVN and one-half of one transferable common share
purchase warrant. Each warrant entitles its holder to subscribe for one common
share at any time before 5:00p.m. (Vancouver time) on February 22, 2010, at an
exercise price of $0.25, subject to Nventa's right to accelerate the expiry
date in the event that the price of Nventa's common shares closes at or above
$0.625 for 20 consecutive trading days on the Toronto Stock Exchange.
The securities offered under this short form prospectus have not been and
will not be registered under the United States Securities Act of 1933, as
amended, or any state securities laws and may not be offered or sold in the
United States or to persons in the United States unless registered or an
exemption from such registration is available.
About Nventa Biopharmaceuticals Corporation:
Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock
Exchange under the symbol NVN.
For more information about Nventa Biopharmaceuticals Corporation, please
visit the company's website located at www.nventacorp.com.
For further information:
For further information: Donna Slade, Director, Investor Relations, 9381
Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Tel: (858) 202-4900,
Fax: (858) 450-6849, email@example.com